Abstract Details

Title A Real-world Study of Inebilizumab for Neuromyelitis Optica Spectrum Disorders

Topic Multiple Sclerosis

Presentation(s) P9 - Poster Session 9 (11:45 AM-12:45 PM)

Poster/Presentation
Number 1-008

Objective This study aimed to evaluate the real-world effectiveness and safety of inebilizumab for patients with AQP4-IgG positive neuromyelitis optica spectrum disorders (NMOSD).

Background

Inebilizumab is a targeting CD19 B cell-depleting monoclonal antibody, and its efficacy and safety in treating NMOSD have been confirmed in the phase III N-MOmentum trial. However, there are limited data reports on its real-world application effects.

Design/Methods We conducted a retrospective analysis of the data from NMOSD patients treated with inebilizumab at a clinical center since 2023. Efficacy of inebilizumab was comprehensively assessed by relapse rate per year, annualized relapse rate (ARR), expanded disability status scale (EDSS) score, number of magnetic resonance imaging (MRI) T2 FLAIR lesions, and B-lymphocyte count. Safety was monitored by tracking laboratory values and adverse events.

Results A total of 42 patients were enrolled in the study, with 4 experiencing relapses, corresponding to a relapse rate of 9.52%. After 6 months of therapy, ARR (0.20±0.69) and EDSS score (2.54±1.79) were both significantly improved compared to pre-treatment (0.81±0.68 and 3.00±1.68, respectively; P<0.05). The number of MRI T2 FLAIR lesions (4.95±5.24) was significantly lower than pre-treatment (6.87±5.07; P<0.05). B-lymphocyte counts decreased to less than 1% within the first half month and all remained at ≤4 cells/μl after 6 months of treatment. A total of 23 patients were co-positive with other autoimmune antibodies, of which 5 had antibody seroconversion after 6 months of treatment. The most frequent adverse event in this study was pulmonary infection, which occurred in 3 patients. Other adverse reactions included elevated uric acid levels and hepatic impairment, with no fatalities reported.

Conclusions The single-center real-world study suggests that inebilizumab can effectively reduce the ARR, EDSS score, and MRI T2 FLAIR lesions in patients with NMOSD, and has a good safety profile, confirming its application value in the real-world.

Authors/Disclosures
Ang Shen PRESENTER	The institution of Miss Shen has received research support from National Natural Science Foundation of China.
Hongbo Liu (the First Affiliated Hospital of Zhengzhou University, Zhengzhou University)	The institution of Hongbo Liu has received research support from China.

��ɫ��

��ɫ��